Five early-career researchers have been awarded four-year fellowships under the LUMC Junior Principal Investigator (PI) Programme 2025. Each...

A new research collaboration between TNO, Logick Energetics B.V., and InnoSer has officially kicked off at Leiden Bio Science Park, supported by a...

The Faculty of Science at Leiden University is offering a new opportunity for professionals to deepen their knowledge of data-driven...

Two mission-driven organisations based at Leiden Bio Science Park have joined forces to improve access to life-saving cell and gene therapies....

𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝘄𝗵𝗲𝗻 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟭𝟱 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗼𝗿𝗴𝗮𝗻𝗶𝘀𝗮𝘁𝗶𝗼𝗻𝘀 𝗼𝗽𝗲𝗻 𝘁𝗵𝗲𝗶𝗿 𝗱𝗼𝗼𝗿𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰? You get an Open Day that brings together over 2,400...

The 2025 Entrepreneurial Ecosystem Index confirms it: the Agglomeration Leiden–Bollenstreek now ranks #3 in the Netherlands, surpassing Brainport and closing in on Amsterdam.

As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living...

Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown...

VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.